美农生物
(301156)
| 流通市值：13.57亿 | | | 总市值：25.59亿 |
| 流通股本：7462.48万 | | | 总股本：1.41亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 99,852,532.57 | 489,929,618.41 | 340,192,520.78 | 207,705,721.73 |
| 营业收入 | 99,852,532.57 | 489,929,618.41 | 340,192,520.78 | 207,705,721.73 |
| 二、营业总成本 | 91,829,115.62 | 437,284,342.38 | 307,311,369.47 | 188,074,708.83 |
| 营业成本 | 71,735,848.19 | 348,751,374 | 242,926,229.13 | 149,364,198.01 |
| 利息支出 | 0 | - | 0 | 0 |
| 手续费及佣金支出 | 0 | - | 0 | 0 |
| 退保金 | 0 | - | 0 | 0 |
| 赔付支出净额 | 0 | - | 0 | 0 |
| 提取保险合同准备金净额 | 0 | - | 0 | 0 |
| 保单红利支出 | 0 | - | 0 | 0 |
| 分保费用 | 0 | - | 0 | 0 |
| 税金及附加 | 1,009,706.43 | 2,780,018.56 | 1,975,993.4 | 1,312,018.91 |
| 销售费用 | 7,846,071.08 | 38,297,378.76 | 26,940,262.53 | 17,400,564.02 |
| 管理费用 | 7,553,145.87 | 31,622,992.24 | 23,251,976.06 | 14,610,727.28 |
| 研发费用 | 4,546,502.11 | 20,882,512.84 | 14,506,680.38 | 8,356,772.3 |
| 财务费用 | -862,158.06 | -5,049,934.02 | -2,289,772.03 | -2,969,571.69 |
| 其中:利息费用 | 2,469.43 | -37,460.23 | -42,511.47 | -49,678.49 |
| 其中:利息收入 | 436,248.45 | 2,913,299.39 | 2,428,821.06 | 1,852,343.98 |
| 加:公允价值变动收益 | -70,896.81 | 1,317,711.16 | 727,222.25 | 368,168.78 |
| 加:投资收益 | 289,668.72 | 384,468.34 | 687,197.1 | 179,583.79 |
| 净敞口套期收益 | 0 | - | 0 | 0 |
| 汇兑收益 | 0 | - | 0 | 0 |
| 资产处置收益 | 2,189.66 | 353,738.08 | 353,254.76 | 20,077.01 |
| 资产减值损失(新) | -611,310.57 | -1,361,351.3 | -982,809.01 | -262,960.37 |
| 信用减值损失(新) | 1,676,312.29 | -1,389,694.13 | -668,622.45 | 42,674.45 |
| 其他收益 | 340,645.75 | 2,568,710.37 | 1,739,613.84 | 1,419,597.94 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 9,650,025.99 | 54,518,858.55 | 34,737,007.8 | 21,398,154.5 |
| 加:营业外收入 | 166,139.53 | 1,500,003.28 | 1,500,002.06 | 1,500,000 |
| 减:营业外支出 | 20,371.8 | 220,004.76 | 56,555.2 | 52,162.04 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 9,795,793.72 | 55,798,857.07 | 36,180,454.66 | 22,845,992.46 |
| 减:所得税费用 | 912,440.29 | 6,216,324.62 | 4,568,832.45 | 2,854,283.32 |
| 六、净利润 | 8,883,353.43 | 49,582,532.45 | 31,611,622.21 | 19,991,709.14 |
| 持续经营净利润 | 8,883,353.43 | 49,582,532.45 | 31,611,622.21 | 19,991,709.14 |
| 终止经营净利润 | - | - | 0 | - |
| 归属于母公司股东的净利润 | 8,883,353.43 | 49,582,532.45 | 31,611,622.21 | 19,991,709.14 |
| 少数股东损益 | - | - | 0 | - |
| (一)基本每股收益 | 0.06 | 0.34 | 0.22 | 0.14 |
| (二)稀释每股收益 | 0.06 | 0.34 | 0.22 | 0.14 |
| 八、其他综合收益 | - | - | 0 | - |
| 归属于母公司股东的其他综合收益 | - | - | 0 | - |
| 九、综合收益总额 | 8,883,353.43 | 49,582,532.45 | 31,611,622.21 | 19,991,709.14 |
| 归属于母公司股东的综合收益总额 | 8,883,353.43 | 49,582,532.45 | 31,611,622.21 | 19,991,709.14 |
| 归属于少数股东的综合收益总额 | - | - | 0 | - |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-30 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |